Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 06462700

Next Previous
Drug Profile

PF 06462700

Alternative Names: Anti-human thymocyte immunoglobulin; Anti-thymocyte globulin - Pfizer; ATGAM; Atgam; Equine; Horse antithymocyte globuline - Pfizer; Lymphocyte immune globulin - Pfizer; PF-06462700

Latest Information Update: 05 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antianaemics; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Aplastic anaemia

Most Recent Events

  • 27 Mar 2023 Registered for Aplastic anaemia in Japan (IV)
  • 26 Mar 2023 Preregistration for Aplastic anaemia in Japan (IV), prior to March 2023
  • 07 Oct 2022 PF 06462700 is still in phase- III trials for aplastic anaemia in Japan (NCT04350606)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top